Kip, G.Turgut, H. C.Alkan, M.Aydin, M. E.Erbatur, M. E.Kiraz, H. A.Kartal, S.2025-10-242025-10-2420150006-92481336-0345https://doi.org/10.4149/BLL_2015_146https://hdl.handle.net/20.500.12899/3901BACKGROUND: Sugammadex is primarily excreted via renal route. We investigated effects of low and high doses of sugammadex (16 mg/kg versus 96 mg/kg) on renal tissue samples of streptozotocin-induced diabetic rats. MATERIAL AND METHODS: Twenty-four Wistar albino rats were divided into 4 groups. Group C (control - 0.9 % NaCl), Group DC (diabetes control; 55 mg/kg streptozotocin, IP, only), Group DR-16S (diabetes-rocuronium - 16 mg sugamnnadex, IV.) and Group DR-96S (diabetes- rocuronium - 96 mg sugammadex, IV). Renal tissue histopathological evaluation and antioxidant status (measurements of MDA levels and NO activities) were studied. RESULTS: Significantly higher levels of all inflammation parameters (inflammation, degeneration/necrosis, tubular dilatation, tubular cell degeneration, dilatation in Bowman's space, tubular hyaline casts, and lymphocyte infiltration) were found in the 96 mg/kg sugammadex group. Higher MDA tissue levels and lower NO activity were found in the 96 mg/kg sugammadex group. DISCUSSION: We can conclude that high-dose (96 mg/kg) sugammadex administration resulted in significant renal tissue damage in diabetic rats. As a consequence, low doses of sugamnnadex have to be preferred in diabetic patients (Tab. 2, Fig. 4, Ref. 26). Text in PDF www.elis.sk.eninfo:eu-repo/semantics/openAccesssugammadex; streptozotocin; diabetes; renal damageArticle10.4149/BLL_2015_14611612746750269241462-s2.0-84973369159Q2WOS:000367280800011Q4